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Alternative mRNA splicing in the region encoding the C-terminus of nuclear receptors results in receptor
variants lacking the entire ligand-binding domain (LBD), or a part of it, and instead contain a sequence of
splice variant-specific C-terminal amino acids. A total of thirteen such splice variants have been shown to
occur in vertebrates, and at least nine occur in humans. None of these receptor variants appear to be able to
bind endogenous ligands and to induce transcription on promoters containing the response element for the
respective canonical receptor variant. Interestingly, ten of these C-terminal splice variants have been shown
to display dominant-negative activity on the transactivational properties of their canonical equivalent. Research
on most of these splice variants has been limited, and the dominant-negative effect of these receptor variants
has only been demonstrated in reporter assays in vitro, using transiently transfected receptors and reporter
constructs.Therefore, the in vivo function and relevance of most C-terminal splice variants remains unclear.
By reviewing the literature on the human glucocorticoid receptor β-isoform (hGRβ), we show that the
dominant-negative effect of hGRβ is well established using more physiologically relevant readouts.The hGR
β-isoform may alter gene transcription independent from the canonical receptor and increased hGRβ levels
correlate with glucocorticoid resistance and the occurrence of several immune-related diseases.Thus, available
data suggests that C-terminal splice variants of nuclear receptors act as dominant-negative inhibitors of
receptor-mediated signaling in vivo, and that aberrant expression of these isoforms may be involved in the
pathogenesis of a variety of diseases.
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Introduction
Molecular mechanisms of nuclear receptor
functioning
The nuclear receptor (NR) superfamily contains
transcriptional regulators that are conserved throughout
various metazoan species, such as nematodes, insects,
and vertebrates [Sluder and Maina, 2001].There are
several molecular mechanisms via which NRs can
influence transcription.
The first mechanism involves unliganded receptors that
are bound in a complex with heat-shock proteins (HSPs).
The interaction with heat-shock proteins prevents the NR
from entering the nucleus and thus ensures its localization
in the cytosol.The ligand-binding domain (LBD) of the
receptor undergoes a conformational change upon ligand
binding, which results in dissociation from the heat-shock
protein complex. Furthermore, this conformational change
exposes the nuclear localization signal (NLS) and
activation function 2 (AF2) domain that are present in the
LBD. After translocation of the ligand-receptor complex
to the nucleus, it forms homodimers or heterodimers with
other NRs and binds with high affinity to nuclear receptor
response elements (NREs) in the promoter regions of
target genes. Subsequent recruitment of cofactors creates
a DNA-bound complex that is capable of remodeling the
chromatin structure and influencing transcription. Usually,
this influence is positive and results in an upregulation of
target genes, but most NRs are also capable of
transcriptional repression through this mechanism.The
mechanism described above is the prevalent model for
transcriptional activation by steroid receptors, like the
glucocorticoid receptor (GR) and estrogen receptor (ER)
[Glass and Ogawa, 2006; Mangelsdorf et al., 1995;
Ribeiro et al., 1995].
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bind constitutively to their NRE, even in the absence of
ligands.This group includes receptors for the thyroid
hormone, vitamin D and retinoic acid, and they are known
to form heterodimers with retinoid X receptors (RXRs).
Without ligand present, this NR-RXR heterodimer is
bound to the response element in a complex with
corepressor proteins.Therefore, receptors from this group
function as active transcriptional repressors in the
absence of ligand. After ligand binding, receptors undergo
a conformational change which removes the corepressor
proteins and replaces them with coactivator proteins.The
removal of the corepressor proteins is thought to be an
active process, which requires ubiquitination- and
proteasome-dependent mechanisms. Similar to the first
NR transcriptional activation mechanism, the recruited
coactivators can make the chromatin structure more
accessible and facilitate the assembly of the general
transcriptional machinery at the promoter [Glass and
Ogawa, 2006; Mangelsdorf et al., 1995; Ribeiro et al.,
1995].
The majority of the so-called orphan receptors (receptors
for which no ligand has been identified (yet)) bind to DNA
as monomers.The methods via which orphan receptors
regulate transcription are not as thoroughly investigated
as for other nuclear receptors. However, orphan receptors
might affect transcription through changes in their
expression or via posttranslational modifications.These
modifications include the phosphorylation or sumoylation
of receptors via GPCRs (G-protein-coupled receptors),
MAPKs (mitogen-activated protein kinases), and PKA
(cAMP-dependent protein kinase). It is also possible that
orphan receptors are activated by ligands that are yet to
be discovered.
Besides activating or repressing genes via binding to
NREs present in promoter regions, some NRs can also
influence transcription via a mechanism called
transrepression, which does not require DNA-binding of
the receptor. Instead, this form of negative regulation
seems to be mediated by inhibiting the activity of other
transcription factors via direct physical interaction.
Examples of transcription factors that are affected by
transrepression are members of the nuclear factor-κB
(NF-κB) and activator protein 1 (AP1) families. Both these
families of transcription factors play crucial roles in
pro-inflammatory signaling pathways and are of great
interest in the treatment of immunity-related diseases
[Glass and Ogawa, 2006; Mangelsdorf et al., 1995;
Ribeiro et al., 1995].
Naturally occurring C-terminal splice variants
of nuclear receptors
Alternative mRNA splicing in the region encoding the
C-terminal end of nuclear receptors results in receptor
variants that lack one or more helices of the LBD, which
are replaced by an alternative amino acid sequence
unique to the splice variant. In this review, we present a
literature study on these LBD splice variants, which
reveals that out of forty-eight nuclear receptor genes
encoded by the human genome, at least nine display this
type of alternative splicing, and that in other species,
several different C-terminal splice variants occur, which
may occur in humans, as well. None of these receptor
variants appear to be able to bind ligand and to induce
transcription on promoters containing the response
element for the respective canonical receptor variant.
Interestingly, almost all LBD splice variants have been
shown to display dominant-negative activity on the
transactivational properties of their canonical equivalent.
Although these receptor variants are highly comparable
in structure and function, the available literature on these
proteins is very scattered.They have never been
described as a group before, and articles on one
C-terminal splice variant hardly ever cite work on a similar
splice variant of another receptor.Therefore, we would
like to provide a broader perspective on C-terminal splice
variants, by considering them as a group of proteins,
rather than individually.The aim of this review is to
provide a structural and functional comparison of these
potential dominant-negative nuclear receptors, which
could lead to a better understanding of their function in
vivo and the molecular mechanisms underlying their
activity. Unfortunately, most of these splice variants have
been poorly studied, so only limited data are available.
The member of this group that has been studied in most
detail is the β-isoform of the glucocorticoid receptor. By
reviewing the literature on this splice variant, we would
like to shed light on the possible in vivo function and
relevance of nuclear receptor C-terminal splice variants
in general.
The ligand-binding domain of nuclear receptors
The LBD of nuclear receptors is involved in several
processes required for transcription initiation, like ligand
binding, binding to coactivator proteins, and dimerization.
Most nuclear receptor LBDs are comprised of 12 α
helices, which are arranged in a three-layer sandwich
[Bourguet et al., 2000; Li et al., 2003;Wurtz et al., 1996].
Helices 1-3 form one outer layer of the sandwich and
helices 6, 7 and 10 form the other outer layer. Helices 4,
5, 8, and 9 form the middle layer, which is absent in the
bottom half of the sandwich, thereby creating a cavity for
ligand binding in most receptors. Upon ligand binding, a
conformational change occurs, which depends on the
nature of the ligand.When an agonist is bound, helix 12,
which contains the AF-2 domain, is packed against
helices 3 and 10 and becomes an integral part of the
LBD.Thereby, it closes the binding pocket and forms,
together with helix 3, 4 and 5, a binding surface for
coactivator proteins [Weatherman et al., 1999].
Coactivators that contain an LXXLL amino acid motif can
interact with this surface [Savkur and Burris, 2004],
enabling optimal transcription initiation by the nuclear
receptor. In most nuclear receptors, LBD-dependent
receptor dimerization is mediated by the N-terminal half
of helix 10, which packs against the same domain in its
dimerization partner. In the resulting dimer, the two helix
10 subunits form a coiled-coil structure. Finally, the
(non-helical) most C-terminal part of the LBD is variable
in length and sequence for different receptors and is
called the F-domain.The precise function of this domain
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been suggested that it stabilizes the conformational state
of the LBD when ligand is bound [Koide et al., 2007;
Ribeiro et al., 1995].
The occurrence of C-terminal splice
variants of nuclear receptors
In this section, thirteen C-terminal splice variants of
nuclear receptors will be described, which are listed in
Table 1. Nine splice variants have been demonstrated to
occur in humans: the glucocorticoid receptor β (GRβ),
estrogen receptor βcx (ERβcx), thyroid hormone receptor
α1 (TRα1), constitutive androstane receptor (sv5)
(CAR(sv5)), dosage-sensitive sex reversal-1α (DAX-1α),
nuclear receptor related 2 (Nurr2), neuron-derived orphan
receptor-2 (NOR-2), peroxisome proliferator-activated
receptorαtr (PPARαtr), and the PPARγ isoform γORF4.
One splice variant has been shown to occur in rats
(vitamin D receptor 1 (VDR1)), one in mouse (CAR2),
and in fish two splice variants named identical to their
human equivalents exist (GRβ in zebrafish and TRα1 in
goldfish), but most likely, they have evolved
independently.
Table 1.  Overview of naturally occurring C-terminal splice variants
of nuclear receptors. All thirteen C-terminal splice variants described
in this review are listed, as well as the splicing mechanism generating
them (see also Figure 1 and Supplementary File 1), and the number of
amino acids lacking from the canonical receptor and the number of
variant-specific amino acids in their C-terminus.
1 Absence in mouse
demonstrated experimentally.
2 Occurrence only demonstrated
experimentally in rat/mouse, not in humans, but most likely conserved
between humans and rodents, based on comparison of genomic
sequence.
3 Presence in mouse/rat demonstrated experimentally.
4 ER:
exon replacement; IR: intron retention; AA: alternative acceptor site usage
(see Figure 1).
5 Could not be determined, due to lack of goldfish genomic
sequence data.
There are three mechanisms which are commonly used
for the generation of C-terminal splice variants of nuclear
receptors (Figure 1).With all three mechanisms, most of
the resulting protein sequence is identical between the
canonical receptor and the splice variant, but a C-terminal
sequence is different.This difference can be a result of
an alternative exon replacing the most 3’ exon(s) of the
mRNA encoding the canonical receptor.This mechanism
is called exon replacement (Figure 1A). Alternatively, an
intronic sequence may be retained as an exon which
replaces the most 3’ exon (Figure 1B). Finally, an
alternative splice acceptor site inside an exon may be
used, which results in a frame shift and an alternative
C-terminal end of the protein (Figure 1C). In all three
cases, the sequence replacing the final exon(s) of the
canonical receptor contains a sequence encoding a
unique C-terminus with no homology to the C-terminus
of the canonical receptor.The generation of TRα2 is more
complicated and involves a combination of alternative
splice donor site usage and exon replacement.The
precise splicing mechanisms for all variants are depicted
in Supplementary File 1.
Figure 1.  Alternative splicing in the C-terminal region of nuclear
receptors. A schematic view of the three commonly used alternative
splicing mechanisms for the generation of C-terminal splice variants of
nuclear receptors. A: exon replacement. Replacing the final exon(s) of
the canonical receptor with an alternative exon and 3’UTR results in a
unique protein ending. B: Intron retention. An intronic sequence is not
spliced out when producing the mRNA, resulting in a premature stop
codon and a unique C-terminal ending. C. Alternative acceptor site usage.
An alternative splice acceptor site inside an exon is used, which results
in a frame shift and an alternative C-terminal end of the protein.
The first group (consisting of hGRβ, hERβcx, rVDR1,
mCAR2/hCAR(sv5), and hDAX-1α) has a point of
divergence between the splice variant and the canonical
receptor in the region close to helix 10.The transcripts
encoding these receptor variants lack only the final exon
of the canonical receptor mRNA (apart from the mCAR2
mRNA, which lacks two exons), which encodes in most
cases between 50 and 100 amino acids. In the second
group (consisting of hNurr2, hNOR-2, hPPARαtr and
hγORF4), a significant part of the LBD (at least 200 amino
acids), which in most cases spans almost the entire LBD,
is replaced by an alternative sequence.The mRNA
encoding these splice variants lacks two to four exons of
the canonical messenger. In Figure 2 and Figure 3, a
schematic representation of the structures of all splice
variants is shown, indicating the divergence points
between the canonical receptor and the splice variant
and their predicted secondary structures.The amino acid
sequences of the different variant-specific C-termini are
shown in Table 2.
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The table shows the variant-specific amino acid sequences in the
C-termini of all thirteen nuclear receptor C-terminal splice variants
described in this review.
Variants of the glucocorticoid receptor (GR)
Glucocorticoids (GCs) are a class of steroid hormones
that are essential in the maintenance of homeostasis and
enable the organism to respond to both physical and
emotional stress. GCs are capable of stimulating
metabolism, while they attenuate immune and
inflammatory processes [Buckingham, 2006]. In 1985,
two human GR (hGR) isoforms were identified and named
hGRα and hGRβ.The canonical receptor, hGRα only
differs from the hGR β-isoform at its C-terminal end.The
first 727 amino acids are identical for hGRα and hGRβ,
after which hGRα has an additional 50 amino acids and
hGRβ has an additional, non-homologous 15 amino acids
[Bamberger et al., 1995; Oakley et al., 1996].The hGR
gene contains 10 exons: exons 1-8, followed by two
copies of exon 9 (exon 9α and 9β for hGRα and hGRβ,
respectively). Alternative splicing between the eighth and
the ninth exon replaces the canonical exon 9α with exon
9β, which leads to the generation of a mRNA encoding
hGRβ [Bamberger et al., 1995; Oakley et al., 1996].This
splicing event results in the absence of helix 12 and part
of helix 11 of the LBD in hGRβ, which is replaced by a
unique C-terminal end [Yudt et al., 2003].
The hGR β-isoform has been detected in a variety of
human cell lines and tissues [Oakley et al., 1996]. At the
mRNA level, hGRβ expression is significantly lower than
the expression of hGRα [Dahia et al., 1997; Mu et al.,
1998; Oakley et al., 1996]. However, this difference is not
observed at the protein level, at which a higher hGRβ
expression level is detected in some cells (e.g., human
neutrophils), as compared to hGRα [de Castro et al.,
1996; Strickland et al., 2001]. Experiments concerning
the expression levels of hGRα and hGRβ revealed that
mRNA transcripts for both hGR isoforms are present at
a ratio of at least 200:1 in different tissues [Oakley et al.,
1996]. Nevertheless, regional or cellular ratios can differ
dramatically from this overall ratio. Furthermore, hGRβ
shows a different subcellular localization than hGRα.
While unliganded hGRα resides in the cytoplasm and
only translocates to the nucleus upon ligand binding,
hGRβ is constitutively present in the nucleus [Oakley et
al., 1997].
Figure 2.  Comparison of the secondary structure at the C-terminal
end of canonical receptors and their splice variants. Predictions of
the secondary structure of canonical NRs and their respective splice
variants are shown at the C-terminal end of the LBD. Helices are indicated
by boxes (with addition of the helix number), while random coil (or beta
sheet) is indicated by a line.The divergence points are marked with a
dotted line, while color differences indicate sequential differences between
the canonical receptor and its splice variant.
The alternatively spliced GR β-isoform is not present in
rodents, due to the absence of the required splice site
[Otto et al., 1997]. So far, the zebrafish is the only other
organism in which the occurrence of a GR β-isoform has
been demonstrated [Schaaf et al., 2008]. Like humans,
the zebrafish genome contains one GR gene, and the
pre-mRNA can be alternatively spliced into a zGRα (the
canonical receptor) and a zGRβ messenger.The structure
and the expression levels of zGRβ are strikingly similar
to its human equivalent [Schaaf et al., 2008].The zGRβ
protein is identical to zGRα for the first 697 amino acids,
after which it contains 40 unique amino acids. Protein
alignment revealed that the divergence point between
zGRα and zGRβ is located at the exact same position as
for hGRα and hGRβ.The two divergence points are
located in helix 11 of the LBD, resulting in an alternative
ending of helix 11 and the absence of helix 12 for both
hGRβ and zGRβ [Goleva et al., 2006; Hauk et al., 2002].
The 40 unique C-terminal amino acids of zGRβ show little
homology to the additional 15 amino acids present in
hGRβ [Schaaf et al., 2008]. As for hGRβ, zGRβ is
expressed at a much lower level than the canonical
receptor isoform, with ratios of zGRα:zGRβ varying from
20:1 to 146:1 [Schaaf et al., 2008].The subcellular
localization of zGRα and zGRβ is similar to the
localization of their human homologs. Unliganded zGRα
is located in the cytosol, while zGRβ is constantly present
in the nucleus [Schaaf et al., 2008].
Although the protein structure of zGRβ closely resembles
that of hGRβ, the splicing event leading to the formation
of the GRβ isoforms is different for humans and zebrafish.
For the human β isoform, its unique C-terminal sequence
is encoded in an alternative version of exon 9, called exon
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zebrafish genome, the unique sequence of GRβ is located
in intron 8.Therefore, hGRβ is created by alternative exon
usage, while zGRβ results from retention of part of intron
8 [Schaaf et al., 2008]. It is likely that zGRβ evolved
independently of hGRβ, since the genetic organization
and β-specific C-terminus of the human and zebrafish
isoforms are different.Therefore, the presence of GRβ
in humans and zebrafish is most likely a case of
convergent evolution, which suggests a significant role
for this isoform in these species.
Variants of the estrogen receptor (ER)
Estrogens are steroid hormones that play key roles in
development and maintenance of normal sexual and
reproductive functions in both men and women [Heldring
et al., 2007].They also exert a vast range of biological
effects in the cardiovascular, musculoskeletal, immune,
and central nervous system.The most potent estrogen
produced in vivo is 17β-estradiol [Heldring et al., 2007].
The two nuclear receptors via which estrogens signal are
named ERα and ERβ. Multiple isoforms exist for both
ERα and ERβ as a result of alternative splicing [Leung
et al., 2006]. One of the ERβ isoforms is the C-terminally
truncated ERβcx (also known as ERβ2) [Ogawa et al.,
1998]. ERβcx is identical to ERβ for the first 469 amino
acids, but the final 61 amino acids of ERβ are replaced
by a unique 26 amino acid sequence in Erβcx [Ogawa et
al., 1998].The canonical ERβ is encoded by 9 exons.
Alternative splicing replaces the final ERβ exon (named
L4) by an exon which is specific for ERβcx (named Lcx).
The splicing mechanism used to create ERβcx is exon
replacement (exon L4 is replaced by exon Lcx [Ogawa
et al., 1998]).
Figure 3.  Comparison of the secondary structure of canonical
receptors and their splice variants Predictions of the secondary
structure of canonical NRs and their respective splice variants are shown
at whole protein level.The region of the DBD is indicated as a reference
point. Helices are indicated by boxes, while random coil (or beta sheet)
is indicated by a line.The divergence points are marked with a dotted
line, while color differences indicate sequential differences between the
canonical receptor and its splice variant.
ERβcx is primarily expressed in testis, ovary, prostate,
and thymus.The relative expression levels of ERβcx and
ERβ vary per tissue [Leung et al., 2006]. ERβcx is
expressed at higher levels than ERβ in testis, while ERβ
expression exceeds ERβcx expression in ovary [Leung
et al., 2006]. Ogawa et al. [Ogawa et al., 1998] predict
that a homolog for ERβcx might also exist for ERα.
However, this type of ERα isoform has yet to be
discovered.
Variants of the thyroid hormone receptor (TR)
Thyroid hormones are regulators of physiological
functions, such as the control of body temperature and
heart rate. Following the secretion of thyroid stimulating
hormone, circulating T4 is converted into T3, which is the
active form of thyroid hormone [Yen, 2001].Thyroid
hormones signal via thyroid hormone receptors (TRs)
present in the nucleus of cells.The two receptors that
mediate T3-regulated gene expression are named TRα
and TRβ [Yen, 2001].The human TRα and TRβ genes
both encode several receptor variants due to alternative
promoter usage and alternative splicing.The different
TRα and TRβ variants are highly homologous in human,
rat and mouse [Yen, 2000]. One of the TRα isoforms that
is generated by alternative splicing was named hTRα2
when it was isolated from a human cDNA library by
Benbrook and Pfahl [Benbrook and Pfahl, 1987]. It differs
from the canonical TRα receptor, hTRα1, at its C-terminal
end.The human TRα gene contains a total of 10 exons.
Usage of a splice donor site in exon 9 (approximately 128
bp downstream of the start of this exon) and an acceptor
site at the 5’ end of exon 10 results in a protein in which
the 40 most C-terminal amino acids of hTRα1 are
replaced by 120 amino acids specific for hTRα2
[Thijssen-Timmer et al., 2006].
Mitsuhashi et al. [Mitsuhashi et al., 1988] demonstrated
that an isoform generated in a similar fashion as hTRα2
also exists in rats.They identified two transcripts that
differ from the 410 amino acids long canonical rTRα
receptor in their C-terminal region. Both these isoforms,
452 and 372 amino acids long, respectively, are
generated by alternative splicing of the rat TRα gene.
The longest isoform is spliced at the same location as
hTRα2, and also replaces the final 40 amino acids of the
canonical receptor with a unique C-terminal end
[Mitsuhashi et al., 1988].
C-terminal splice variants of TRα have also been
identified in goldfish. Nelson and Habibi [Nelson and
Habibi, 2006] analyzed goldfish cDNA for the occurrence
of alternative TR transcripts and found two alternatively
spliced TRα isoforms.The two truncated goldfish TRα
(gTRα) isoforms were named TRα2 and TRα-truncated.
gTRα-truncated is only 206 amino acids long, and similar
to the canonical gTRα1 (466 amino acids) until the hinge
region [Nelson and Habibi, 2006]. gTRα2 is similar to
gTRα1 for the first 324 amino acids, after which the final
142 amino acids of gTRα1 are replaced by 54
variant-specific amino acids in gTRα2 [Nelson and Habibi,
2006].The hTRα2 and gTRα2 isoforms are similar in that
they both lose homology with their respective TRα1
counterparts in the C-terminal region of the LBD.
Nevertheless, hTRα2 and gTRα2 are spliced in different
regions of the TRα gene, and have different C-terminal
endings. Unfortunately, the complete genomic sequence
of the goldfish TRα gene is unknown, which makes it
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in detail.
Variants of the vitamin D receptor (VDR)
The biologically-active metabolite of vitamin D is called
1,25-dihydroxyvitamin D3 (further referred to as vitamin
D3).Vitamin D3 is important in the metabolism of minerals,
and in the formation and growth of bone [Demay, 2006].
The biological actions of vitamin D3 are mediated by the
vitamin D receptor (VDR). In the rat, a VDR isoform has
been identified which differs from the canonical receptor
at its C-terminal end [Ebihara et al., 1996]. Alternative
splicing generates an isoform which has retained intron
8 of the canonical rat vitamin D receptor (rVDR0). A stop
codon within intron 8 truncates the C-terminal region of
this isoform (named rVDR1). As a result, rVDR1 lacks
the most C-terminal 86 amino acids of rVDR0.These
amino acids are replaced by 19 variant-specific amino
acids. Analysis of the genomic structure and sequence
of the rVDR gene demonstrated that the inserted
sequence corresponds to the entire intron between exon
8 and 9 [Ebihara et al., 1996].The rVDR1 transcript is
expressed at 1/15th to 1/20th of the level of rVDR0
expression [Ebihara et al., 1996]. Both rVDR0 and rVDR1
are primarily expressed in the intestines and the kidney,
and rVDR1 was only detected in mature rats, not in
embryos [Ebihara et al., 1996].
To date, a dominant-negative VDR isoform has only been
identified in rats. However, allelic variations in intron 8 of
the hVDR gene can be used to predict the density of bone
[Ebihara et al., 1996]. Intron 8 of the hVDR gene
corresponds to the intron that is retained in the rVDR
gene for the formation of rVDR1.Therefore, a similar
splicing mechanism may exist for the hVDR gene.
Variants of the constitutive androstane receptor
(CAR)
The constitutive androstane receptor (CAR) was originally
identified as an orphan receptor. Later, CAR was found
to act as a receptor for foreign compounds, known as
xenobiotics [Timsit and Negishi, 2007].Together with the
pregnane X receptor (PXR), CAR performs a pivotal role
in hepatic drug metabolism.To date, no definitive
physiological ligand has been identified for CAR. Instead,
CAR responds to a range of toxic by-products of
endogenous metabolism and to exogenous chemicals
[Timsit and Negishi, 2007].The genetic organization of
CAR has been studied in humans and mice. Both genes
contain 9 exons and share a high degree of sequence
similarity throughout the DNA-binding and ligand-binding
domain [Choi et al., 1997].The human CAR gene can
generate a C-terminally spliced receptor isoform.The
canonical hCAR is 352 amino acids long, while the
truncated hCAR splice variant 5 (hCAR(sv5)) isoform is
only 317 amino acids long [Arnold et al., 2004]. Alternative
splice acceptor site usage in exon 9 leads to a deletion
of the first 76 base pairs of this exon. Consequently, the
final 42 amino acids of hCAR are replaced by 7 amino
acids, which are specific for hCAR(sv5) due to a frame
shift [Arnold et al., 2004].
The canonical human CAR (hCAR) is expressed in the
liver, kidney, spleen, testis, and small intestines. In
contrast, the hCAR(sv5) isoform was shown to be present
in every tissue studied, with the exception of the small
intestine [Arnold et al., 2004].Therefore, most tissues
only contain the truncated hCAR(sv5) isoform.The
subcellular localization of hCAR(sv5) is similar to that of
hCAR [Arnold et al., 2004].
In mouse, the canonical CAR is named mCAR1. A
C-terminal splice variant, named mCAR2, is identical to
mCAR1, except for the most C-terminal 78 amino acids
present in mCAR1 [Choi et al., 1997].These amino acids
are replaced by 6 variant-specific amino acids in mCAR2
[Choi et al., 1997].The mCAR2 isoform is generated by
replacement of exon 8 and 9 with an alternative exon that
is located between these exons [Choi et al., 1997].The
mouse CAR1 and CAR2 are primarily expressed in the
liver. Compared to the expression of mCAR1, the mCAR2
variant is expressed at relatively low levels [Choi et al.,
1997].
Variants of dosage-sensitive sex reversal-1
(DAX-1)
The orphan nuclear receptor named dosage-sensitive
sex reversal-1 (DAX-1) provides another interesting
example of the generation of a C-terminal receptor splice
variant. DAX-1 plays an important role in the development
and functioning of the adrenal gland and the
hypothalamic-pituitary-adrenal axis [Hossain et al., 2004].
Furthermore, DAX-1 is a transcriptional repressor of
several genes involved in steroid hormone metabolism
and acts as a corepressor of steroidogenic factor 1 (SF-1),
ERα, and ERβ [Hossain et al., 2004]. DAX-1 is an unusual
nuclear receptor, since it is encoded by only two exons
and lacks the characteristic zinc-finger DNA-binding motif
that is highly conserved in other nuclear receptors
[Hossain et al., 2004].The human DAX-1 gene generates
two distinct isoforms via the usage of an alternative
version of the second exon [Hossain et al., 2004].The
mRNA encoding the canonical receptor, DAX-1, combines
exon 1 with the normal version of exon 2 to generate a
protein that contains 470 amino acids. Combining exon
1 with the alternative exon 2a results in the generation of
DAX-1α (401 amino acids long), which contains a unique
C-terminal sequence compared to DAX-1.
The canonical DAX-1 receptor is expressed in the adrenal
gland, brain, fetal kidney, ovary, pancreas, and testis.
DAX-1α is also present in these tissues, but was also
detected in all other human tissues which were examined
[Hossain et al., 2004]. DAX-1α is expressed at higher
levels than DAX-1 in all tissues, except in the testis, where
DAX-1 expression is higher [Hossain et al., 2004]. So far,
this DAX-1 splice variant has only been discovered in
humans.
Variants of the nuclear receptor related 1 (Nurr1)
The NGFI-B family of nuclear receptors consists of
NGFI-B, Nurr1, and NOR1. All three members of the
NGFI-B family are orphan receptors, since no ligands
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receptors have been implicated in many biological
processes, such as neural differentiation, cell growth, and
T-cell apoptosis [Ohkura et al., 1999]. Nevertheless, little
is known about the molecular mechanisms via which they
affect these processes [Ohkura et al., 1999].
The mouse Nurr1 gene contains 8 exons, of which the
first two are non-coding [Saucedo-Cardenas et al., 1997].
A C-terminally truncated variant of mouse Nurr1 is named
Nurr2 [Ohkura et al., 1999].The most C-terminal amino
acids of Nurr2 are derived from alternative usage of a
splice acceptor site in exon 6, ending in an in-frame
stop-codon. In addition, Nurr2 is generated by alternative
splicing in exon 1 and 2, resulting in a shorter N-terminal
region, as well.The occurrence of Nurr2 is conserved in
at least mouse, rat, and human [Ohkura et al., 1999].
Nurr1 and Nurr2 are expressed ubiquitously in all
examined tissues in these species [Ohkura et al., 1999].
In each tissue, Nurr2 is expressed at significantly lower
levels than Nurr1.
Variants of the neuron-derived orphan
receptor-1 (NOR-1)
A C-terminal splice variant also exists for the NGFI-B
family member NOR-1, which is named NOR-2
[Petropoulos et al., 1995]. NOR-2 has so far been found
in humans [Ohkura et al., 1998], rat [Petropoulos et al.,
1995] and mouse [Maltais and Labelle, 2000].The
full-length hNOR-1 is 626 amino acids long, while hNOR-2
only contains 443 amino acids. hNOR-2 is generated by
retention of the intron between exon 5 and 6, which
contains a premature stop-codon and the 3’UTR.The
mRNA encoding hNOR-2 lacks exons 6, 7, and 8 [Maltais
and Labelle, 2000].The variant-specific amino acid
sequence is 10 amino acids long in mouse and rat and
25 amino acids long in humans [Ohkura et al., 1998].
Variants of the peroxisome proliferator-activated
receptor α (PPARα)
The peroxisome proliferator-activated receptors (PPARs)
are ligand-dependent receptors involved in lipid
homeostasis, energy metabolism, inflammation, and
cellular differentiation and proliferation [Kim et al., 2006].
Endogenous ligands for the PPARs include free fatty
acids and eicosanoids.
There are three PPARs: PPARα, PPARβ (also known as
PPARδ), and PPARγ. A splice variant within the
C-terminal region of the human PPARα has been
described and named PPARαtr [Gervois et al., 1999;
Palmer et al., 1998]. PPARα is encoded by 7 exons and
is 468 amino acids long, whereas PPARαtr is only 174
amino acids long. PPARαtr mRNA is generated by
retention of the intronic sequence at the 3’ end of exon
5. PPARαtr mRNA lacks exon 6, 7 and 8 [Hamid et al.,
1999; Mlodzik et al., 1990]. PPARαtr mRNA is expressed
in several human tissues and represents 20-50% of total
PPARα mRNA [Gervois et al., 1999; Palmer et al., 1998].
PPARαtr has only been identified in humans.
Variants of the peroxisome proliferator-activated
receptor γ (PPARγ)
The PPARκ gene consists of 6 exons and a C-terminal
splice variant, γORF4, is generated by retention of intronic
sequence at the 3’ end of exon 4 [Kim et al., 2006;
Sabatino et al., 2005].The final two exons of the mRNA
encoding the canonical receptor, exons 5 and 6, are
deleted from the transcript.This results in a protein that
is identical to PPARγ for the first 243 amino acids and
contains 21 additional amino acids coded for by intron 4
sequences [Kim et al., 2006; Sabatino et al., 2005]. Like
PPARαtr, γORF4 has only been identified in humans.
The function of C-terminal splice
variants of nuclear receptors
Loss of ligand binding and transactivation
activity
Binding to cognate ligand has not been reported for any
of the described nuclear receptor splice variants. As is
known from structural studies, the C-terminal region of
the LBD that is lacking in these variants is required for
ligand binding and apparently, the variant-specific
C-terminal amino acids do not have the characteristics
to fulfill this role.
In addition to the lack of ligand binding ability, all
described splice variants lack the ability to transactivate
gene transcription induced by a promoter containing their
cognate response element.This has been shown in
experiments with reporter assays using transient
transfection of the reporter plasmid. For the non-orphan
receptors, this obviously could be explained by the
inability to bind ligand and become activated. However,
all described receptor variants also lack the AF-2
containing C-terminal helix of the LBD, which is replaced
by an alternative C-terminus.The inability to transactivate
may therefore also be due to the variant-specific
C-terminal sequence not having the characteristics to
substitute for the function of the AF-2 domain, with the
result that the surface required for the docking of
LXXLL-motif-containing coactivators cannot be formed.
Moreover, the alternative C-terminus apparently keeps
the receptor variant in a conformation that does not allow
the AF-1 to be functional, since this domain, together with
an intact DNA-binding domain (DBD), can be sufficient
for transactivation activity in reporter assays [Hollenberg
et al., 1987].
Dominant-negative activity
Ten splice variants described have been shown to act as
dominant-negative inhibitors of the activity of their
respective canonical receptor. In most cases, this has
been demonstrated in reporter assays in which the
canonical receptor, the splice variant and a plasmid
containing a reporter gene (CAT or luciferase) driven by
a promoter containing the response element for the
respective receptor, were transiently transfected into
cultured cells.The only splice variant that fails to show
dominant-negative activity in such an assay is the mouse
CAR2 isoform, which does not inhibit the transactivation
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dominant-negative activity of the human CAR splice
variant hCAR(sv5) and the goldfish TRα2 was not studied,
and the dominant-negative activity of DAX-1α was studied
in a different assay. DAX-1α was demonstrated to inhibit
the ability of the canonical receptor DAX-1 to repress
SF-1-induced transactivation in transiently transfected
reporter assays [Hossain et al., 2004].
The dominant-negative activity of hGRβ appears to
depend on two amino acids (a lysine and a proline), which
are present in the hGRβ-specific C-terminal 15 amino
acid sequence, rather than on the absence of the AF-2
containing helix 12 [Yudt et al., 2003]. It has been shown
that these two amino acids play a role in the nuclear
localization of hGRβ [Yudt et al., 2003].
The dominant-negative activity of the splice variant is not
always specifically affecting the activity of the respective
canonical receptor, but may affect other members of the
nuclear receptor family, as well. mNurr2 inhibits
transactivation of all members of the NGFI-B family
[Ohkura et al., 1999]. hTRα2 shows dominant-negative
activity on hTRα1 and hTRβ, but also on hRARβ and
hER-induced transactivation on the same (TRE-driven)
promoter [Hermann et al., 1991]. hPPARαtr shows
inhibition of hPPARα, hPPARγ, hHNF-4, hRORα and
hGRα [Gervois et al., 1999]. hERβcx shows
dominant-negative activity on hERα (surprisingly, not on
hERβ-induced transactivation [Ogawa et al., 1998]). In
contrast, rVDR1 seems to specifically inhibit rVDR0, since
it has been demonstrated not to inhibit transactivation
induced by the closely related receptors TR and RAR on
promoters containing their cognate response elements
[Ebihara et al., 1996]. hGRβ shows dominant-negative
activity over hGRα and hMR [Bamberger et al., 1995;
Bamberger et al., 1997; Oakley et al., 1996], but not over
hAR- and hPR-induced transactivation [Oakley et al.,
1996], whereas all four receptors are able to induce
transcription on the same response element.
Mechanism of action of dominant-negative
activity
Three mechanisms via which receptor variants with
dominant-negative activity can interfere with canonical
receptor signaling have been proposed [Yen, 2000], and
they are shown in Figure 4.
Occupation of response elements
The first mechanism involves competition for DNA binding
on NREs by dominant-negative receptors. In this case,
competition for a limited amount of NREs results in a
reduced transcriptional activity of the canonical receptor.
This competition can occur by both homodimerized
dominant-negative receptors and by heterodimeric
complexes consisting of a dominant-negative receptor
and its canonical equivalent or another binding partner
(e.g., the retinoid X receptor (RXR)). Indeed, rVDR1,
hTRα2 [Hermann et al., 1991; Katz and Lazar, 1993],
and hERβcx [Moore et al., 1998; Ogawa et al., 1998]
inhibited the DNA-binding of their canonical receptors in
gel shift assays, even though the affinity of the latter two
splice variants is significantly reduced compared to the
canonical receptors.
Figure 4. Three possible mechanisms for the dominant-negative
activity of C-terminal splice variants of nuclear receptors. In the left
panel, transactivation by nuclear receptors is shown in the absence of an
inhibitor. Nuclear receptors can bind to their response elements as a
homodimer, a heterodimer (e.g., with RXR), or as a monomer. In the right
panel, transactivation is inhibited due to the presence of a
dominant-negative inhibitor, that either occupies the response elements
(1), forms transcriptionally-inactive heterodimers with the canonical
receptor (2), or competes for binding with transcriptional coactivator
proteins (3).
The affinity for the cognate response elements differs
largely between splice variants, suggesting that this
mechanism is not relevant for all splice variants. Rat
NOR-2 [Petropoulos et al., 1995] and hDAX-1α [Hossain
et al., 2004] bind to their response element with the same
affinity as their cognate canonical receptor in gel shift
assays. Other splice variants show significantly reduced
DNA binding in vitro (hERβcx [Moore et al., 1998; Ogawa
et al., 1998], hGRβ [Oakley et al., 1999], hTRα2 [Hermann
et al., 1991; Katz and Lazar, 1993], hγORF4 [Kim et al.,
2006], mNurr2 [Ohkura et al., 1999]), or do not bind to
their response elements at all (hPPARαtr [Gervois et al.,
1999], mCAR2 [Choi et al., 1997], and hCAR(sv5) [Arnold
et al., 2004]).
Heterodimerization
A second mechanism proposed is the formation of dimers
between canonical receptors and the dominant-negative
form, which are transcriptionally inactive and prevent the
formation of active receptor complexes. Several
techniques have been used to demonstrate these
heterodimers, and in most studies dimerization was
observed. Immunoprecipitation studies have shown that
hGRβ-hGRα heterodimers occur in human neutrophils
[Strickland et al., 2001] and after overexpression of hGRβ
in mouse hybridoma cells [Hauk et al., 2002]. Using
pull-down assays, hGRβ has been shown to interact with
hGRα [Yudt et al., 2003], and hERβcx with hERα (and
to a lesser extent with hERβ [Ogawa et al., 1998]). Using
gel-shift assays, hERβcx has been demonstrated to
dimerize with both hERα and hERβ on DNA [Moore et
al., 1998], and similarly rVDR1 and rVDR0 [Ebihara et
al., 1996], and hTRα2 and hTRα1 [Hermann et al., 1991]
have been found to dimerize on DNA (although the latter
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[Katz and Lazar, 1993]).
For nuclear receptors of subfamily 1 (e.g., TR, VDR, CAR,
PPAR), that depend on dimerization with RXR for their
transactivational activity, splice variants may dimerize
with RXR, thereby forming an inactive dimer. However,
rVDR1 [Ebihara et al., 1996], hTRα2 [Katz and Lazar,
1993], mCAR2 [Choi et al., 1997], and hCAR(sv5) [Arnold
et al., 2004] were shown to be unable to dimerize with
RXR on NREs. Only hγORF4 was shown to dimerize with
RXR on DNA [Kim et al., 2006].
Competition for coactivators
The third possible mechanism for dominant-negative
activity is titration of cofactors by the
transcriptionally-inactive receptors. Protein-protein
interactions between the dominant-negative receptor
isoforms and limited amounts of cofactors can interfere
with canonical receptor activity, since these cofactors
form the link between the liganded receptor and the basal
transcription machinery. Several coactivators that interact
with the AF-1 have been suggested to play a role. For
example, overexpression of CBP has been shown to
prevent the inhibition of hPPARα-induced transactivation
by hPPARαtr [Gervois et al., 1999], and overexpression
of TIF2/GRIP1 attenuates the suppressive effect of hGRβ
on transactivation by hGRα, through interaction with the
AF-1 [Charmandari et al., 2005]. In contrast, since all
described splice variants lack a functional AF-2 domain,
it is unlikely that coactivators interacting with this region
will bind to these splice variants. Indeed, TIF1α has been
shown not to interact with hERβcx in a pull down assay
[Ogawa et al., 1998], and the coactivators SRC-1,
TIF2/GRIP1/SRC-2, ACTR/SRC-3, and DRIP205 have
been shown not to interact with hCAR(sv5) in a
mammalian two-hybrid assay [Arnold et al., 2004].
In vivo relevance; lessons from hGRβ
The dominant-negative role of hGRβ
Although evidence for a dominant-negative role for
C-terminal splice variants of nuclear receptors is
mounting, the physiological role of these receptors may
still differ from what has been observed in the in vitro
studies. All results regarding the repression of the activity
of canonical receptors are obtained from studies based
on transfection experiments, using vectors containing
reporter assays as a measure for transcriptional activity.
These experiments provide convincing evidence that the
splice variants inhibit (part of) the transactivational activity
of their canonical receptor in this experimental setup.
However, these receptor variants do not necessarily
behave similarly in vivo. For instance, reporter assays
with vectors containing nuclear receptor response
elements (NREs) lack the condense chromatin packaging
in which genomic DNA is wrapped in vivo.Therefore,
NREs in reporter assays are more accessible than
promoter regions of endogenous NR target genes.The
delicate mechanisms required for transcription initiation,
like chromatin remodeling, histone acetylation and
methylation are overlooked in this experimental setup.
In addition to these in vitro reporter assays, the
transcription of endogenous genes has been used as
readout in several studies on hGRβ. Li et al. [Li et al.,
2006] have used the glucocorticoid-induced increase in
the expression of MKP-1 mRNA and the decrease of
TNFα and IL-6 mRNA expression as readout for the
sensitivity to glucocorticoids [Li et al., 2006].This
sensitivity was significantly increased in monocytes after
treating them with anti-hGRβ siRNA. A similar siRNA
experiment was performed in BAL macrophages in which
the glucocorticoid-induced increase in MKP-1 transcription
was enhanced after knocking down the hGRβ expression
[Goleva et al., 2006]. Overexpression of hGRβ in mouse
DO-11.10 hybridoma cells resulted in a decreased
induction of MKP-1 mRNA following treatment with the
synthetic glucocorticoid dexamethasone [Goleva et al.,
2006]. In cells derived from human eye tissue (trabecular
meshwork cells), overexpression of hGRβ inhibited the
dexamethasone-induced increase in the expression of
the endogenous genes myocilin and fibronectin [Zhang
et al., 2005b].
More cell-biological readouts have been used in several
other studies on the dominant-negative effect of hGRβ.
Increasing the expression of hGRβ by transfection of
mouse neutrophils results in a decreased rate of
dexamethasone-induced cell death [Strickland et al.,
2001]. Overexpression of hGRβ in mouse DO-11.10
hybridoma by viral transduction reduced the inhibition of
cell proliferation by several glucocorticoids [Hauk et al.,
2002].Transient overexpression of hGRβ prevented the
glucocorticoid-induced inhibition of phagocytosis in human
NTM-5 cells [Zhang et al., 2007].
In summary, the dominant-negative activity of hGRβ is
well established. It has been shown to inhibit the activity
of hGRα in reporter assays. In addition, it has been shown
to inhibit glucocorticoid-induced changes in the expression
of endogenous genes. Interestingly, this was observed
for genes that are activated by glucocorticoids (MKP-1,
myocilin, fibronectin) and for genes that are repressed in
response to glucocorticoids (TNFα, IL-6), which occurs
independently of the receptor’s DNA binding ability.
Finally, hGRβ has been demonstrated to inhibit
glucocorticoid-induced changes in several physiological
properties in a number of cell types.
hGRβ as a regulator of transcription
independent from hGRα
Besides its role as a dominant-negative inhibitor, hGRβ
may act as a regulator of transcription independent from
hGRα.Three studies show such a role for hGRβ. First,
stable overexpression of hGRβ in U-2 OS cells (which
do not express hGRα or hGRβ endogenously) resulted
in altered transcription of more than 5,000 genes in a
microarray study, of which approximately half were
increased and half decreased [Lewis-Tuffin et al., 2007].
Second, stable overexpression of green fluorescent
protein (GFP)-tagged hGRβ in HeLa cells also showed
that hGRβ has intrinsic transcriptional activity [Kino et al.,
2009]. It was shown to regulate the expression of a large
number of genes negatively or positively.Third, in
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shown to, just like hGRα, transrepress the activity of other
transcription factors like AP-1 and NF-κB. Overexpression
of hGRβ attenuated NF-κB- and AP-1-induced activation
in luciferase assays [Gougat et al., 2002] and the
GATA3-induced activity of the IL-5 and IL-13 promoters
driving a luciferase gene [Kelly et al., 2008].Thus,
although limited data are available, a role for hGRβ
independent from hGRα is suggested.
Increased expression of hGRβ and
glucocorticoid resistance in vitro
Treatment of cells with pro-inflammatory cytokines like
IL-1 or TNFα [Webster et al., 2001], IL-2 and IL-4 [Leung
et al., 1997], IL-8 [Strickland et al., 2001], IFNα and IFNγ
[Tliba et al., 2008], and IL-7 or IL-18 [Orii et al., 2002] has
been shown to induce the expression of hGRβ mRNA
and/or protein in several studies.TNFα treatment changes
the hGRα:hGRβ protein ratio in HeLa cells from 4:1 to
1:2, resulting from a 4-fold increase in hGRβ and a 2-fold
increase in hGRα protein expression [Webster et al.,
2001]. IL-8 was shown to induce the expression of hGRβ
protein 2-fold (without affecting hGRα levels) in
neutrophils, changing the already low hGRα:hGRβ protein
ratio in these cells from 1:4 to 1:8 [Strickland et al., 2001].
The splice factor SRp30 has been suggested to be
involved in this process, since it was shown to direct the
alternative splicing to hGRβ in these cells [Xu et al., 2003].
These treatments also resulted in decreased sensitivity
to glucocorticoids, as measured by reduced DNA binding
of hGRα [Leung et al., 1997], reduced transactivational
activity in reporter assays [Webster et al., 2001], and
reduced transcriptional activity using CD38 repression
as a readout [Tliba et al., 2008]. In addition, microbial
super-antigens have been demonstrated to induce the
expression of hGRβ and to induce glucocorticoid
resistance, as demonstrated by a reduced inhibition of
the proliferative response to glucocorticoids in human
PBMCs [Hauk et al., 2002] and by the inhibition of
glucocorticoid-induced IL-2 repression in a nasal explant
model [Fakhri et al., 2004]. However, in none of the
studies mentioned here, has it been demonstrated
whether the decrease in sensitivity is due to the increased
hGRβ expression, or to other effects of the cytokine
treatment.
Several human cell types have been shown to have
relatively high levels of hGRβ expression [Oakley et al.,
1997; Pujols et al., 2002].These high expression levels
have been shown to correlate with insensitivity to
glucocorticoids. For example, human monocytes have
significantly higher hGRβ levels than T cells, and display
a slower glucocorticoid induction of MKP-1 and
glucocorticoids fail to repress the IL-6 expression in these
cells [Li et al., 2006]. In addition, in monocytes GRα
translocates to the nucleus more slowly in response to
glucocorticoid treatment (an effect also seen after
overexpression of hGRβ in mouse hybridoma cells
[Goleva et al., 2006]).
Increased expression of hGRβ and
glucocorticoid resistance in vivo
In a large number of studies, increased hGRβ expression
has been shown to correlate with resistance to
glucocorticoid treatment in patients suffering from several
immune-related diseases, suggesting that hGRβ plays
an important role in glucocorticoid resistance in these
patients. An increased expression of hGRβ has been
demonstrated in various immune cells, particularly T-cells,
from glucocorticoid-resistant asthma patients [Goleva et
al., 2006; Hamid et al., 1999; Leung et al., 1997; Sousa
et al., 2000]. In addition, in patients suffering from nasal
polyposis [Hamilos et al., 2001], Crohn’s disease [Towers
et al., 2005], ulcerative colitis [Honda et al., 2000; Zhang
et al., 2005a], and leukemia [Shahidi et al., 1999], a
similar correlation between increased hGRβ levels and
glucocorticoid resistance was observed. Goleva et al.
[Goleva et al., 2006] demonstrated a causal relationship
between hGRβ expression levels and glucocorticoid
resistance by decreasing the hGRβ expression level using
specific RNA silencing in broncheoalveolar lavage cells
from glucocorticoid-resistant asthma patients, which
enhanced the glucocorticoid responsiveness in these
cells. Finally, a correlation has been found between
increased expression of hGRβ and the occurrence of
several immune-related diseases. In various immune
cells of severe asthma patients [Bergeron et al., 2006;
Christodoulopoulos et al., 2000], and patients suffering
from ulcerative colitis [Orii et al., 2002], leukemia [Shahidi
et al., 1999], ankylosing spondylitis (Bechterew’s disease
[Lee et al., 2005]), nasal polyposis [Hamilos et al., 2001],
or severe systemic lupus erythematosus [Piotrowski et
al., 2007] increased expression levels of this receptor
isoform were found.
A single-nucleotide polymorphism in the glucocorticoid
receptor gene in the region encoding the 3’UTR of hGRβ
mRNA results in a mRNA with increased stability in vitro
[Derijk et al., 2001; Schaaf and Cidlowski, 2002] and this
polymorphism is associated with the occurrence of
rheumatoid arthritis [Derijk et al., 2001].This
polymorphism is therefore considered to increase the
expression of hGRβ in carriers, although this has never
been demonstrated. Interestingly, this polymorphism
appears to affect only certain glucocorticoid-induced
changes in gene expression. In PBMLs derived from
carriers, the glucocorticoid-induced transrepression of
IL-2 mRNA expression was reduced, but the induction of
GILZ mRNA expression by glucocorticoids was not
different from non-carriers [van den Akker et al., 2006b].
In addition, the risk of nasal carriage of Staphylococcus
aureus is reduced [van den Akker et al., 2006a], whereas
the risk of cardiovascular disease is increased [van den
Akker et al., 2008].
Thus, relatively high expression levels of hGRβ have
been found in cells under certain conditions in vitro, in
specific cell types in vivo, and in patients suffering from
a variety of immune-related diseases. In all cases, this
increased expression appears to correlate with a
decreased sensitivity to glucocorticoids, although the
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resistance has not directly been established in any of
these studies.
Ligand binding of hGRβ
It has been shown that hGRβ is capable of binding the
synthetic hGRα antagonist RU486 [Lewis-Tuffin et al.,
2007]. Addition of RU486 increased the fraction of hGRβ
residing in the nucleus in COS and U-2 OS cells, whereas
a series of 57 related steroids did not affect subcellular
localization of hGRβ. A similar effect of RU486 was found
for zGRβ in COS and ZF4 (zebrafish fibroblast) cells
(Schaaf, unpublished results). Furthermore, RU486
administration alters the regulation of approximately 1,000
genes in hGRβ-overexpressing U-2 OS cells (and not in
wild type U-2 OS cells), of which the majority (~75%)
were repressed. However, in a different study, no altered
transcriptional activity or nuclear translocation of hGRβ
was observed following addition of RU486 in HCT116
cells (derived from a human colon carcinoma) [Kino et
al., 2009].These studies suggest that RU486 might have
cell-specific effects on the activity of hGRβ.
Discussion
In the present review, data on thirteen different C-terminal
splice variants have been discussed. Nine human nuclear
receptor genes have been demonstrated to show this
type of alternative splicing, out of a total of forty-eight
nuclear receptor genes in the human genome.The
significant number of described C-terminal splice variants
suggests that these splice variants play an important role
in nuclear receptor functioning. Although many nuclear
receptors have been studied in great detail, it is
conceivable that several more nuclear receptor genes
encode a C-terminal splice variant, but that this has not
yet been described for these genes.
The most likely function of these splice variants is to act
as a dominant-negative inhibitor of the canonical receptor,
since this type of dominant-negative inhibition has been
shown for many of the described receptor variants.Ten
splice variants have been demonstrated to have
dominant-negative activity on their cognate canonical
receptor in reporter assays, and only one (mCAR2) failed
to display this type of activity in these assays.The human
GR β-isoform, the best studied member of this group,
was not only studied in reporter assays, but it has also
been shown to have dominant-negative activity on
endogenous gene regulation by the canonical hGRα, and
on glucocorticoid-induced alterations in cell physiology.
These data suggest that the data from reporter assays
can, at least in part, be extrapolated to the regulation of
endogenous genes.
In addition, it is possible that the C-terminal splice variants
described in this review function as transcription factors
independent from their cognate canonical receptor, since
it has been shown that hGRβ is able to regulate gene
transcription independent from hGRα [Gougat et al., 2002;
Kino et al., 2009; Lewis-Tuffin et al., 2007]. Although this
latter activity of hGRβ has not been studied in detail yet,
future studies on other C-terminal splice variants may
uncover this type of functionality for these receptors, as
well.
For the dominant-negative activity of these splice variants,
three possible mechanisms of action have been
suggested. First, occupation of response elements,
although most receptor splice variants showed no or
decreased DNA binding. Second, the formation of inactive
heterodimers with the canonical receptor. For some
C-terminal variants, such dimers with the canonical
receptor have indeed been shown for some variants to
occur in living cells. Furthermore, DNA binding of several
of these dimers was demonstrated in vitro using gel shift
assays.Third, competition for coactivators has been
proposed. Although some variants have been shown to
interact with specific coactivators, limited data are
available to get a good overview of coactivator binding
of the splice variants.Thus, none of the three proposed
mechanisms could be excluded, and possibly all three
mechanisms play a role.The level at which they
contribute to this activity may differ between receptors,
and this could be due to structural differences between
the splice variants.
Due to their dominant-negative activity, the splice variants
may play an important role in the regulation of the activity
of their cognate canonical receptor in vivo.We
hypothesize that these splice variants are capable of
blunting (part of) the activity of their respective canonical
receptors, which may occur in cells or tissues where the
splice variant is expressed at high enough levels for
dominant-negative regulation to take place. Since these
canonical receptors play important physiological roles,
aberrant expression of the splice variants may underlie
several pathological conditions. For hGRβ, a role in
glucocorticoid resistance and pathogenesis of several
immune-related diseases is strongly suggested, as
discussed in detail above. For other nuclear receptors,
the in vivo relevance is less clear. For example, in some
studies the presence of hERβcx and hERβ is correlated
with better prognosis in breast cancer [Palmieri et al.,
2004; Sugiura et al., 2007], while in others the presence
of hERβcx is of no influence on the development of
carcinomas [Yen, 2000]. In addition, allelic variations in
intron 8 of the human VDR gene (which is the intron
retained for the formation of rVDR1 mRNA) can be used
to predict the density of bone [Ebihara et al., 1996].
Involvement in tumorigenesis in colorectal cancers has
been suggested for the hPPARγ splice variant hγORF4
[Sabatino et al., 2005].These interesting observations
indicate that a better understanding of the role of nuclear
receptor splice variants may help to elucidate the
molecular mechanism of the pathogenesis of a variety of
diseases. In addition, the observation that hGRβ is able
to bind the synthetic ligand RU486, which alters its activity
[Lewis-Tuffin et al., 2007], suggests that opportunities
exist to exploit these splice variants as potential drug
targets.
Comparison of the structure of these thirteen receptor
isoforms yielded two interesting observations. First, two
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(hGRβ/zGRβ, hERβcx, hTRα1/gTRα1, rVDR1,
mCAR2/hCAR(sv5), and hDAX-1α) have a
splice-variant-specific tail that starts around helix 10.The
variants of the second group (hNurr2, hNOR-2, hPPARαtr
and hγORF4) have almost the entire LBD replaced by an
alternative sequence. Second, the splice variant-specific
C-terminal amino acid sequences are highly
heterogeneous (see Table 2).They do not appear to show
any homology or to share common domains, suggesting
that the splice variant-specific amino acid sequence is
not important for the dominant-negative activity. Indeed,
structure-function studies on hGRβ demonstrated that
out of fifteen splice variant-specific amino acids, only two
amino acids, that caused a distortion in the (helical)
structure of the receptor’s C-terminus, were required for
the dominant-negative activity of this receptor isoform
[Yudt et al., 2003].These data, together with the lack of
similarity between the different C-termini of the different
splice variants, suggest that many alternative C-termini
may result in dominant-negative activity, but that some
specificity exists.
When we compared genomic sequences from human,
mouse, chicken, clawed frog and zebrafish, it was shown
that the splice sites required for the generation of
C-terminal splice variants are relatively well conserved
between human and mouse, but not between human and
non-mammalian species (data not shown). Of the splice
variants that occur in humans and rodents, only hGRβ
and hERβcx appear not to be conserved between human
and mouse. Interestingly, conservation of the amino acid
sequence of the C-terminal tail of the splice variants is
very poor, even between human and mouse. Only the
sequences specific for TRα2 and CAR2 are more than
50% identical between human and mouse.Thus, similar
to our findings when we compared sequences of the
different splice variants, we found very little similarity in
the C-terminal sequence of splice variants that are
orthologs. Both findings suggest low selective pressure
on most of these sequences.
In conclusion, many C-terminal splice variants of nuclear
receptors exist, which probably play a role as
dominant-negative inhibitors of the activity of the
canonical receptor. Most of the sequences of their
C-terminus may not be critical for this function.We
suggest an important role for these receptor isoforms,
controlling or fine-tuning the activity of nuclear receptors.
Supplementary Material
Supplementary File 1: Genetic organization of the NR
LBD splice variant genes.The intron and exon structure
of the NR genes and resulting mRNAs and proteins are
shown. Splicing events are depicted with dotted lines.
The numbers above the proteins indicate the first and
final amino acid positions, as well as the divergence point.
The location of the DNA-binding domain (DBD) in the
proteins serves as a reference point. a.1: hGRβ is
generated by replacing exon 9α with exon 9β. a.2: In
contrast to hGRβ, zGRβ is created when intron 8β is
retained. b: ERβcx is generated by replacing exon L4
with exon Lcx. c.1: hTRα1 is generated by using a cryptic
splice donor site in exon 9 combined with an alternative
exon 10. c.2: Goldfish TRα1 and gTRα2 proteins. Due
to the lack of genomic sequence data, the splicing
mechanism is unknown. d: rVDR1 is generated by
retention of intron 8. e.1: hCAR(sv5) is generated using
an alternative splice acceptor site in exon 9. e.2: mCAR2
is generated by replacing exon 8 by exon 8’. f: DAX-1α
is generated by replacing exon 2 by exon 2a. g: Nurr2 is
generated by alternative splice acceptor site usage in
exon 6. Alternative acceptor site usage occurs in exon 1
and 2 as well, but this is not indicated in this figure since
it is beyond the scope of this review. h: mNOR-1 is
generated by alternative splice acceptor site usage in
exon 5. i: PPARαtr is generated by retention of the intron
between exon 5 and 6. j:γORF4 is generated by retention
of the intron between exon 4 and 5.
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